Differential risk of adverse drug reactions with baricitinib across age groups: integrating real-world pharmacovigilance and genetic causal inference.

This study examined the safety of baricitinib, a medication used to treat autoimmune conditions like rheumatoid arthritis, but does not relate to acupuncture treatment. Researchers analyzed over 5,300 adverse event reports from 2018-2024 to understand how side effects differ between younger (18-65 years) and older (66+ years) patients. They found that infections were the most common side effect overall, occurring in about 28% of cases. Older patients showed higher rates of serious blood clots, including deep vein thrombosis and pulmonary embolism, while younger patients more frequently experienced elevated liver enzymes and certain cancers. Using genetic analysis, researchers discovered that natural variations in JAK1 and JAK2 genes may explain some cardiovascular risks: higher JAK2 activity appeared protective against blood clots, while higher JAK1 activity increased irregular heartbeat risk. Most side effects occurred shortly after starting the medication. This pharmaceutical study highlights important age-related differences in drug safety but has no direct connection to acupuncture practice or treatment. For patients with rheumatoid arthritis or other immune-mediated conditions, acupuncture may serve as a complementary therapy alongside conventional treatments, though this study does not address acupuncture's role. If you're considering acupuncture for arthritis or pain management, consult with a licensed acupuncturist certified by the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM).

This pharmacovigilance study analyzed 5,354 baricitinib-associated adverse drug reactions reported to FAERS (Q3-2018 to Q1-2024), stratified by age groups (18-65 vs ≥66 years). Methodology included disproportionality analysis using Reporting Odds Ratio and Bayesian Confidence Propagation Neural Network, time-to-onset modeling, and two-sample Mendelian randomization with eQTL-based instruments. Infections comprised 28.3% of reports. Elderly patients showed increased thrombotic events (DVT, PE), while younger adults demonstrated higher hepatic enzyme elevation and malignancy rates. MR analysis indicated JAK2 expression was protective against thrombosis (OR=0.998, p=0.028), while JAK1 expression increased atrial fibrillation risk (OR=1.255, p=0.043). Clinical takeaway: This pharmaceutical study does not pertain to acupuncture practice. For practitioners treating arthritis patients on baricitinib, awareness of age-stratified cardiovascular and hepatic risks may inform collaborative care decisions.